Alfonso Sanchez-Munoz

Malaga, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Journal: Breast (Edinburgh, Scotland)
Published: February 13, 2026

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Journal: Frontiers in oncology
Published: June 16, 2025

Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature.

Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature.

Journal: Frontiers in oncology
Published: April 26, 2024

Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.

Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.

Journal: Biomedicines
Published: July 06, 2022

High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.

High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.

Journal: International journal of molecular sciences
Published: July 01, 2022

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

Journal: European journal of cancer (Oxford, England : 1990)
Published: July 07, 2021

Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.

Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: August 19, 2020

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.

Journal: Frontiers in oncology
Published: June 16, 2019

Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.

Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.

Journal: The Journal of urology
Published: June 05, 2019

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.

Journal: Frontiers in oncology
Published: May 14, 2019

Targeted treatment approaches in refractory germ cell tumors.

Targeted treatment approaches in refractory germ cell tumors.

Journal: Critical reviews in oncology/hematology
Published: April 09, 2019

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Journal: Breast care (Basel, Switzerland)
Published: October 16, 2018
Showing 1-12 of 63

Last Updated: 09/26/2026